Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial (vol 402, pg 775, 2023)

被引：0
|
作者：
Pozo-Rosich, P.
Ailani, J.
Ashina, M.
机构：
来源：
LANCET | 2023年 / 402卷 / 10404期
关键词：
D O I：
10.1016/S0140-6736(23)01812-3
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：774 / 774
页数：1
相关论文
共 50 条
  • [1] Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial (vol 402, pg 775, 2023)
    Pozo-Rosich, P.
    Ailani, J.
    Ashina, M.
    LANCET, 2023, 402 (10410): : 1328 - 1328
  • [2] Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo- controlled, phase 3 trial
    Pozo-Rosich, Patricia
    Ailani, Jessica
    Ashina, Messoud
    Goadsby, Peter J.
    Lipton, Richard B.
    Reuter, Uwe
    Guo, Hua
    Schwefel, Brittany
    Lu, Kaifeng
    Boinpally, Ramesh
    Miceli, Rosa
    Ferreira, Rosa De Abreu
    Mccusker, Emily
    Yu, Sung Yun
    Severt, Lawrence
    Finnegan, Michelle
    Trugman, Joel M.
    LANCET, 2023, 402 (10404): : 775 - 785
  • [3] Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial
    Croop, Robert
    Lipton, Richard B.
    Kudrow, David
    Stock, David A.
    Kamen, Lisa
    Conway, Charles M.
    Stock, Elyse G.
    Coric, Vladimir
    Goadsby, Peter J.
    LANCET, 2021, 397 (10268): : 51 - 60
  • [4] Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
    Tepper, Stewart
    Ashina, Messoud
    Reuter, Uwe
    Brandes, Jan L.
    Dolezil, David
    Silberstein, Stephen
    Winner, Paul
    Leonardi, Dean
    Mikol, Daniel
    Lenz, Robert
    LANCET NEUROLOGY, 2017, 16 (06): : 425 - 434
  • [5] Oral emergency contraception with levonorgestrel plus piroxicam: a randomised double-blind placebo-controlled trial (vol 402, pg 851, 2023)
    Khabir, Yumna
    LANCET, 2023, 402 (10405): : 850 - 850
  • [6] Double-blind placebo-controlled trial of tonabersat in the preventive management of migraine
    Goadsby, P. J.
    Ferrari, M. D.
    Olesen, J.
    Mills, J. G.
    CEPHALALGIA, 2007, 27 (10) : 1195 - 1196
  • [7] Onset of Migraine Preventive Effects With Rimegepant in a Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Trial
    Lipton, R. B.
    Kudrow, D.
    Smith, T.
    Croop, R.
    Jensen, C. M.
    Kamen, L.
    Thiry, A.
    Coric, V.
    Goadsby, P. J.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 18 - 19
  • [8] Onset of Migraine Preventive Effects With Rimegepant in a Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Trial
    Lipton, R. B.
    Kudrow, D.
    Smith, T.
    Croop, R.
    Jensen, C. M.
    Kamen, L.
    Thiry, A.
    Coric, V.
    Goadsby, P. J.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 27 - 28
  • [9] Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial
    Pozo-Rosich, P.
    Ailani, J.
    Ashina, M.
    Goadsby, P.
    Lipton, R.
    Reuter, U.
    Guo, H.
    Schwefel, B.
    Boinpally, R.
    McCusker, E.
    Yu, S. Yun
    Finnegan, M.
    Trugman, J.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [10] Atogepant for the preventive treatment of chronic migraine: Results from the PROGRESS phase 3 trial
    Pozo-Rosich, P.
    Goadsby, P. J.
    HEADACHE, 2022, 62 (07): : 923 - 923
12345